key: cord-0019288-jpjjq50c
authors: Stella, Michele; Falzone, Luca; Caponnetto, Angela; Gattuso, Giuseppe; Barbagallo, Cristina; Battaglia, Rosalia; Mirabella, Federica; Broggi, Giuseppe; Altieri, Roberto; Certo, Francesco; Caltabiano, Rosario; Barbagallo, Giuseppe Maria Vincenzo; Musumeci, Paolo; Ragusa, Marco; Pietro, Cinzia Di; Libra, Massimo; Purrello, Michele; Barbagallo, Davide
title: Serum Extracellular Vesicle-Derived circHIPK3 and circSMARCA5 Are Two Novel Diagnostic Biomarkers for Glioblastoma Multiforme
date: 2021-06-27
journal: Pharmaceuticals (Basel)
DOI: 10.3390/ph14070618
sha: 24e806d13f11a9a7a3d33f5befee319f947fc36a
doc_id: 19288
cord_uid: jpjjq50c

Glioblastoma multiforme (GBM) is the most frequent and deadly human brain cancer. Early diagnosis through non-invasive biomarkers may render GBM more easily treatable, improving the prognosis of this currently incurable disease. We suggest the use of serum extracellular vesicle (sEV)-derived circular RNAs (circRNAs) as highly stable minimally invasive diagnostic biomarkers for GBM diagnosis. EVs were isolated by size exclusion chromatography from sera of 23 GBM and 5 grade 3 glioma (GIII) patients, and 10 unaffected controls (UC). The expression of two candidate circRNAs (circSMARCA5 and circHIPK3) was assayed by droplet digital PCR. CircSMARCA5 and circHIPK3 were significantly less abundant in sEVs from GBM patients with respect to UC (fold-change (FC) of −2.15 and −1.92, respectively) and GIII (FC of −1.75 and −1.4, respectively). Receiver operating characteristic curve (ROC) analysis, based on the expression of sEV-derived circSMARCA5 and circHIPK3, allowed us to distinguish GBM from UC (area under the curve (AUC) 0.823 (0.667–0.979) and 0.855 (0.704 to 1.000), with a 95% confidence interval (CI), respectively). Multivariable ROC analysis, performed by combining the expression of sEV-derived circSMARCA5 and circHIPK3 with preoperative neutrophil to lymphocyte (NLR), platelet to lymphocyte (PLR) and lymphocyte to monocyte (LMR) ratios, three known diagnostic and prognostic GBM markers, allowed an improvement in the GBM diagnostic accuracy (AUC 0.901 (0.7912 to 1.000), 95% CI). Our data suggest sEV-derived circSMARCA5 and circHIPK3 as good diagnostic biomarkers for GBM, especially when associated with preoperative NLR, PLR and LMR.

Glioblastoma multiforme (GBM) is the most common malignant and highly aggressive primary brain tumor in adults, with a median post-diagnosis overall survival of 16 months, despite the current therapeutical approach based on surgical resection, followed by chemotherapy and radiotherapy [1] [2] [3] . According to the World Health Organization (WHO) classification, GBM is a grade IV glioma, with several unique features that characterize its aggressiveness and unresponsiveness to therapy [1, 4] . GBM is typically a heterogeneous cancer, characterized by a wide range of genetic and epigenetic intraand inter-tumor variability [5, 6] ; its microenvironment is made up of several cell types: glioma cells, glioma stem cells (GSC), stromal cells that include resident glial cells such as oligodendrocytes, astrocytes, ependymal cells, and microglia and infiltrating immune cells such as monocytes, macrophages, and lymphocytes [7] . Glioma cells reside in a niche of stromal cells and communicate with them to establish a cancer progression-promoting environment through cell-cell gap junctions, the secretion of effector biomolecules including growth factors, cytokines, chemokines, and extracellular vesicles (EVs) [2, [8] [9] [10] .

EVs are a heterogeneous group of lipid bilayer-delimited particles that can be classified into various subtypes such as exosomes, ectosomes, microvesicles, and apoptotic bodies, based on their biogenesis (budding or active secretory pathway), size (ranging from 30 to 2000 nm), and molecular structure [11] [12] [13] . EVs are involved in several biological functions thanks to their role in the transfer of different species of RNAs and other bioactive molecules from donor to proximal or distant recipient cells through body fluids [14] [15] [16] [17] [18] [19] [20] . The number and cargo of EVs may change according to physiological or pathological conditions; in several cancers, it has been shown that the quality and quantity of their cargo appear to be altered and differentially expressed (DE) molecules (mainly, RNAs and proteins) have been suggested as diagnostic or prognostic biomarkers of disease [21] [22] [23] [24] [25] .

Circular RNAs (circRNAs) are covalently closed RNA molecules, mostly non-coding, mainly synthesized starting from pre-mRNA produced by protein-coding genes through back-splicing [26, 27] . Their particular structure renders them intrinsically resistant to degradation mediated by exonucleases and, consequently, more stable than their linear isoform counterparts, both inside and outside cells [28] . Most studies describe circRNAs as involved in the regulation of gene expression (e.g., acting as microRNA (miRNA) or RNA binding protein (RBP) sponges) [29] [30] [31] [32] . CircRNAs show species, tissue, and developmental stage-specific expression patterns; in addition to being expressed inside cells (especially in the cytoplasm), they have been found as cargo components of EVs [33] [34] [35] [36] . The expression of circRNAs has been found to be dysregulated in several pathological conditions, including gliomas and GBM [34, [37] [38] [39] [40] [41] [42] [43] . We recently characterized circSMARCA5 as a tumor-suppressive circRNA, downregulated in GBM tissue when compared to normal brain parenchyma; its expression is inversely correlated with: (i) overall and progressionfree survival of GBM patients; (ii) pro-to anti-angiogenic VEGFA mRNA isoform ratio; and (iii) microvascular density of GBM tissue [31] . Mechanistically, we determined that circSMARCA5 physically interacts with the oncoprotein SRSF1 through its GAUGAA RNA motif: mutation of this motif determined a significant decrease in the binding between the two molecules with related downstream effects on GBM cell migration and angiogenic potential [32, 44] . To further characterize the molecular phenotype of GBM patients, we assayed the expression of circSMARCA5 and other circRNAs known to be dysregulated in GBM in EVs isolated from serum (sEVs) of GBM patients and compared these data to those from unaffected controls (UC).

qNano Gold analysis performed on sEVs isolated from GBM and UC samples revealed: (i) a mean modal diameter of 117 and 118.5 nm ( Figure 1A) ; (ii) a mean concentration of 2.10 × 10 9 and 2.42 × 10 9 particles/mL ( Figure 1B 

qNano Gold analysis performed on sEVs isolated from GBM and UC samples revealed: (i) a mean modal diameter of 117 and 118.5 nm ( Figure 1A) ; (ii) a mean concentration of 2.10 × 10 9 and 2.42 × 10 9 particles/mL ( Figure 1B ), respectively; and (iii) a majority of particles sized between 100 and 200 nm ( Figure 1C ,D). Qualitative analysis of sEVs, performed through immunogold labeling followed by transmission electron microscopy (TEM), showed their positivity to the tetraspanin CD81 (Supplementary Figure S1 ). 

Among the circRNAs known to be DE in GBM, circSMARCA5 and circHIPK3 appeared as the top two most expressed in sEV cargo, in physiological conditions, according to exoRBase (Table 1) . Droplet digital PCR (ddPCR) confirmed the expression of both circRNAs in sEVs isolated from UC and revealed their significant underexpression in sEVs from GBM (circSMARCA5 and circHIPK3 fold-change (FC) = −2.15 and −1.92, pvalue = 0.00028 and 0.00034, Student's t-test, respectively) (Figure 2A,B) . sEV-derived circSMARCA5 and circHIPK3 were also underexpressed in GBM as compared to GIII (FC = −1.75 and −1.4, p-value = 0.026 and 0.10, Student's t-test, respectively) (Figure 2A,B) . The expression of circSMARCA5 and circHIPK3 within EVs from GBM sera did not significantly correlate with their expression assayed in matched GBM tissues, derived from the same patients ( Figure 2C ,D). 

Among the circRNAs known to be DE in GBM, circSMARCA5 and circHIPK3 appeared as the top two most expressed in sEV cargo, in physiological conditions, according to exoRBase (Table 1) . Droplet digital PCR (ddPCR) confirmed the expression of both circR-NAs in sEVs isolated from UC and revealed their significant underexpression in sEVs from GBM (circSMARCA5 and circHIPK3 fold-change (FC) = −2.15 and −1.92, p-value = 0.00028 and 0.00034, Student's t-test, respectively) ( Figure 2A ,B). sEV-derived circSMARCA5 and circHIPK3 were also underexpressed in GBM as compared to GIII (FC = −1.75 and −1.4, p-value = 0.026 and 0.10, Student's t-test, respectively) ( Figure 2A ,B). The expression of circSMARCA5 and circHIPK3 within EVs from GBM sera did not significantly correlate with their expression assayed in matched GBM tissues, derived from the same patients ( Figure 2C ,D). 

Hematological analysis revealed a significant increase in the percentage of neutrophils (among white blood cells) and of two known diagnostic and prognostic inflammatory markers of GBM (the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR)-see Discussion) in GBM patients as compared to UC (Supplementary Figure S2) . The percentage (among white blood cells) and the count lymphocytes, as well as the lymphocyte to monocyte ratio (LMR) (another marker whose low level is linked to a dismal prognosis of GBM patients-see Discussion), significantly decreased in GBM patients as compared to UC (Supplementary Figure S2) . The amount of sEV-derived circSMARCA5 and circHIPK3 positively correlated with the number of platelets, the percentage and the total number of lymphocytes, while it negatively correlated with the percentage of neutrophils and NLR; moreover, PLR and LMR negatively and positively correlated with the amount of sEV-derived circHIPK3, respectively (Figure 3 ). 

Hematological analysis revealed a significant increase in the percentage of neutrophils (among white blood cells) and of two known diagnostic and prognostic inflammatory markers of GBM (the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR)-see Discussion) in GBM patients as compared to UC (Supplementary Figure S2) . The percentage (among white blood cells) and the count lymphocytes, as well as the lymphocyte to monocyte ratio (LMR) (another marker whose low level is linked to a dismal prognosis of GBM patients-see Discussion), significantly decreased in GBM patients as compared to UC (Supplementary Figure S2) . The amount of sEV-derived circSMARCA5 and circHIPK3 positively correlated with the number of platelets, the percentage and the total number of lymphocytes, while it negatively correlated with the percentage of neutrophils and NLR; moreover, PLR and LMR negatively and positively correlated with the amount of sEV-derived circHIPK3, respectively ( Figure 3) . 

Receiver operating characteristic curve (ROC) analysis based on the expression of sEV-derived circSMARCA5 and circHIPK3 allowed us to distinguish GBM from UC (area under the curve (AUC) 0.823 (0.667-0.979) and 0.855 (0.704 to 1.000), with a 95% confidence interval (CI), respectively). Multivariable ROC analysis, performed by combining the expression of sEV-derived circSMARCA5 and circHIPK3 with preoperative NLR, PLR and 

Receiver operating characteristic curve (ROC) analysis based on the expression of sEV-derived circSMARCA5 and circHIPK3 allowed us to distinguish GBM from UC (area under the curve (AUC) 0.823 (0.667-0.979) and 0.855 (0.704 to 1.000), with a 95% confidence interval (CI), respectively). Multivariable ROC analysis, performed by combining the expression of sEV-derived circSMARCA5 and circHIPK3 with preoperative NLR, PLR and LMR, allowed an improvement in the GBM diagnostic accuracy (AUC 0.901 (0.7912 to 1.000), 95% CI) (Figure 4 ). 

The interest in finding new non-invasive cancer biomarkers for diagnostic, prognostic and response-to-therapy purposes has been increasing in the last few years [45] [46] [47] [48] . This is one of the first studies that focuses on circRNAs as non-invasive diagnostic biomarkers, detectable in GBM patients' liquid biopsies: to the best of our knowledge, only Chen et al. published a paper on three plasmatic circRNAs (circFOXO3, circ_0029426, and circ-SHPRH) with a diagnostic value for GBM [49] . Due to their intrinsic resistance to exonucleases and resulting high stability, circRNAs, and especially EV-associated circRNAs, may be considered very good candidate biomarkers [42, 45] . Here, we focused on circSMARCA5 and circHIPK3: the first is a known tumor suppressor, whereas the second is an oncogenic circRNA in GBM cells [30] [31] [32] 50] . In addition, both circRNAs have been detected in sEVs, according to ExoRBase, a database storing circRNA expression data in sEVs in physiological and pathological conditions [51] . CircSMARCA5 has been defined as a biomarker for atherosclerosis, hepatocellular carcinoma and gastric cancer, and has been found in plasma, serum and whole blood [36, [52] [53] [54] [55] [56] . CircHIPK3 has been detected in human umbilical cord mesenchymal stem cell-derived exosomes, and its release to ischemic muscle seems to contribute to the repair of damaged tissue [57] . CircHIPK3 has also been suggested as a diagnostic and prognostic biomarker, detectable in the serum exosomes and whole serum of colorectal cancer, chronic myeloid leukemia and nasopharyngeal carcinoma patients [58] [59] [60] . Both circRNAs were significantly less abundant in sEVs from GBM when compared to UC, and their expression appeared to be significantly positively correlated. Our data also suggest that the differential expression of sEV-derived circSMARCA5 and circHIPK3 is independent from that observed in GBM tissue. The lack of this correlation may be due to dysregulated EV production and EV 

The interest in finding new non-invasive cancer biomarkers for diagnostic, prognostic and response-to-therapy purposes has been increasing in the last few years [45] [46] [47] [48] . This is one of the first studies that focuses on circRNAs as non-invasive diagnostic biomarkers, detectable in GBM patients' liquid biopsies: to the best of our knowledge, only Chen et al. published a paper on three plasmatic circRNAs (circFOXO3, circ_0029426, and circ-SHPRH) with a diagnostic value for GBM [49] . Due to their intrinsic resistance to exonucleases and resulting high stability, circRNAs, and especially EV-associated circRNAs, may be considered very good candidate biomarkers [42, 45] . Here, we focused on circSMARCA5 and circHIPK3: the first is a known tumor suppressor, whereas the second is an oncogenic circRNA in GBM cells [30] [31] [32] 50] . In addition, both circRNAs have been detected in sEVs, according to ExoRBase, a database storing circRNA expression data in sEVs in physiological and pathological conditions [51] . CircSMARCA5 has been defined as a biomarker for atherosclerosis, hepatocellular carcinoma and gastric cancer, and has been found in plasma, serum and whole blood [36, [52] [53] [54] [55] [56] . CircHIPK3 has been detected in human umbilical cord mesenchymal stem cell-derived exosomes, and its release to ischemic muscle seems to contribute to the repair of damaged tissue [57] . CircHIPK3 has also been suggested as a diagnostic and prognostic biomarker, detectable in the serum exosomes and whole serum of colorectal cancer, chronic myeloid leukemia and nasopharyngeal carcinoma patients [58] [59] [60] . Both circRNAs were significantly less abundant in sEVs from GBM when compared to UC, and their expression appeared to be significantly positively correlated. Our data also suggest that the differential expression of sEV-derived circSMARCA5 and circHIPK3 is independent from that observed in GBM tissue. The lack of this correlation may be due to dysregulated EV production and EV cargo from non-tumoral cells such as brain or blood cells in GBM patients [61] . The latter hypothesis is supported by the positive correlation between the expression of both circRNAs and the number of platelets, as well as the percentage and the total number of lymphocytes that we found in our cohort of GBM patients and UC. It is known that platelets and lymphocytes are among the major contributors of EVs in serum [62, 63] , and both cell types express circSMARCA5 and circHIPK3 [64] [65] [66] . Furthermore, GBM cells are able to "educate" platelets and other blood formed elements, modifying their transcriptome and splicing pattern [67, 68] , which suggests that blood cells, and especially platelets, lymphocytes or both, may contribute to the dysregulated expression of sEV-derived circSMARCA5 and circHIPK3 that we observed in GBM patients with respect to UC. The diagnostic and clinical relevance of the altered expression of sEV-derived circSMARCA5 and circHIPK3 in GBM is supported by their correlation with NLR, PLR and LMR. The diagnostic and prognostic value of these inflammatory markers in GBM has been largely described in the literature [69] [70] [71] [72] . According to these data, a multivariable ROC analysis, performed by combining the expression of sEV-derived circSMARCA5 and circHIPK3 with NLR, PLR and LMR, allowed an improvement in the diagnostic value as compared to a univariable analysis: this is in accordance with other studies, confirming the strength of a diagnosis based on a multibiomarker panel [73] [74] [75] .

Sera from 23 GBM and 5 GIII patients and 10 UC were obtained from whole blood collected in sterile BD Vacutainer ® SST II Advance tubes with clot activator (Becton Dickinson and Company, NJ, USA). Blood samples were collected both from GBM patients, before neurosurgery, and from controls, during check-ups at the day hospital at the Azienda Ospedaliero-Universitaria "Policlinico Vittorio Emanuele", Catania, Italy. Once the whole blood samples clotted, serum was collected and centrifuged twice at 2150× g for 15 at room temperature to pellet potential residual blood cells. Supernatants were stored at −80 • C until further processing. GBM tissue biopsies were collected from the same patients and stored at −80 • C until further processing, as previously described [31] . All patients were diagnosed for GBM by at least three experienced pathologists, according to the 2016 WHO criteria [4] . Informed consent was obtained from all subjects involved in the study. The study was approved by the local ethics committee of the Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Catania, Italy. Age, sex and clinical features of the GBM patients and UC are reported in Table 2 . 

Hemolysis of serum samples was evaluated through spectrophotometric analysis. The absorbance of a representative 100 µL aliquot from each sample was measured at two wavelengths (λ = 541 nm and 576 nm) using the Synergy 2-BioTek plate reader (Agilent Technologies, Inc., Santa Clara, CA, USA): only samples with an absorbance value <0.2 were considered non-hemolyzed and were used for further processing [76] . Briefly, a 1 mL aliquot from non-hemolyzed sera was thawed at 4 • C and centrifuged at 1500× g, 10 , 4 • C; the supernatant was centrifuged again at 8000× g, 10 , 4 • C to remove potential debris: supernatants from the second centrifugation were used for sEV isolation. sEVs were isolated from 500 uL of serum by using SEC, through qEV original/70nm chromatography columns (IZON Science, Christchurch, New Zealand). Sterile PBS, filtered through 0.2 µm filters, was used as eluent and pooled fractions 7-10 were collected in a final volume of 2 mL and stored at −80 • C until further processing, according to the manufacturer's instructions. For three randomly chosen GBM and control samples, an aliquot of 100 µL was assayed by TRPS through qNano Gold (IZON Science) to determine the size and the 

EVs were lysed with five volumes of QIAzol Lysis Reagent (Qiagen, Venlo, Netherlands, EU) and RNA was extracted using miRNeasy Mini Kit (Qiagen), following the manufacturer's instructions. cDNA was obtained using SuperScript™ II Reverse Transcriptase (ThermoFisher Scientific, Waltham, MA, USA), according to the manufacturer's protocol. cDNA was amplified through ddPCR using QX200 ddPCR EvaGreen Supermix™ (Bio-Rad Laboratories, Inc., Hercules, CA, USA), as previously described [77, 78] . ddPCR data analysis was performed using QuantaSoft™ Analisys Pro Software V1.0. GAPDH was used as endogenous control RNA. GBM tissues were processed as previously described to obtain RNA [31] . Purified RNA was amplified through qRT-PCR using Power SYBR ® Green RNA-to-CT™ 1-Step Kit (ThermoFisher Scientific), in a 7900HT Fast real-time PCR system (ThermoFisher Scientific). Primer sequences used in this study are reported in Table 3 . Table 3 . Primer sequences used in this study.

Primer Sequence 

Differential expression between GBM and control groups, ROC curves and AUCs were calculated by using IBM ® SPSS ® v. 23 and GraphPad Prism v. 8.0.2. In particular, binary logistic regression was used to build a probabilistic model by combining the expression of multiple markers: ROC curve was generated, accordingly. Normal distribution of gene expression data was assessed by Kolmogorov-Smirnov test of normality. Differential expression analysis between GBM and control groups was defined through Student's two-tailed t-test. Pearson's correlation coefficient was calculated to define positive and negative correlations. p-values < 0.05 were considered statistically significant.

Our data convincingly suggest sEV-derived circSMARCA5 and circHIPK3 as new good diagnostic GBM biomarkers, especially when combined with preoperative NLR, PLR and LMR data.

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013

FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series

Supramarginal resection of glioblastoma: 5-ALA fluorescence, combined intraoperative strategies and correlation with survival

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary

Glioblastoma heterogeneity and cancer cell plasticity

The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease

Multidimensional communication in the microenvirons of glioblastoma

Extracellular vesicles in the tumor microenvironment: Old stories, but new tales

Extracellular Vesicles in Glioblastoma Tumor Microenvironment

Peritumoral Microenvironment in High-Grade Gliomas: From FLAIRectomy to Microglia-Glioma Cross-Talk

Exosomes: Biogenesis, biologic function and clinical potential

The biology, function, and biomedical applications of exosomes

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

Extracellular vesicles as a platform for liquid biopsy in glioblastoma patients

MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): A platform for glioblastoma biomarker development

BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

Liquid biopsy: Monitoring cancer-genetics in the blood

Ovarian aging increases small extracellular vesicle CD81(+) release in human follicular fluid and influences miRNA profiles

A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker

Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis

Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer

Detection of Pancreatic Ductal Adenocarcinoma by A qPCR-based Normalizer-free Circulating Extracellular Vesicles RNA Signature

Diagnostic accuracy of cerebrospinal fluid and serum-isolated extracellular vesicles for glioblastoma: A systematic review and meta-analysis

Circular RNAs are a large class of animal RNAs with regulatory potency

The RNA binding protein quaking regulates formation of circRNAs

A view of pre-mRNA splicing from RNase R resistant RNAs

Natural RNA circles function as efficient microRNA sponges

CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB

CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1

The GAUGAA Motif Is Responsible for the Binding between circSMARCA5 and SRSF1 and Related Downstream Effects on Glioblastoma Multiforme Cell Migration and Angiogenic Potential

Exosomal circRNAs: A new star in cancer

Circular RNAs Co-Precipitate with Extracellular Vesicles: A Possible Mechanism for circRNA Clearance

Circular RNAs in body fluids as cancer biomarkers: The new frontier of liquid biopsies

Identification and Characterization of Circular RNAs As a New Class of Putative Biomarkers in Human Blood

Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types

Emerging Role of Circular RNAs in Cancer

Biogenesis and Function of Circular RNAs in Health and in Disease

Circular RNAs: Functions and Prospects in Glioma

Functions and clinical significance of circular RNAs in glioma

Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme

Diagnostic Utility of the Immunohistochemical Expression of Serine and Arginine Rich Splicing Factor 1 (SRSF1) in the Differential Diagnosis of Adult Gliomas

Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. Cell

Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer

Proteomic and immunologic analyses of brain tumor exosomes

Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma

Plasmatic circRNA Predicting the Occurrence of Human Glioblastoma

CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling

A database of circRNA, lncRNA and mRNA in human blood exosomes

Plasma circular RNA hsa_circ_0001445 and coronary artery disease: Performance as a biomarker

Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma

A map of human circular RNAs in clinically relevant tissues

Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis

Zuo, X. circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer

Stem cell-derived exosomes prevent pyroptosis and repair ischemic muscle injury through a novel exosome/circHIPK3/ FOXO3a pathway

Circular RNA circHIPK3 serves as a prognostic marker to promote chronic myeloid leukemia progression

Upregulation of circRNA_0000285 serves as a prognostic biomarker for nasopharyngeal carcinoma and is involved in radiosensitivity

LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions

Eosinophils and other peripheral blood biomarkers in glioma grading: A preliminary study

Platelet-derived Extracellular Vesicles: An Emerging Therapeutic Approach

Platelets, endothelial cells and leukocytes contribute to the exercise-triggered release of extracellular vesicles into the circulation

Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia

Circular RNA enrichment in platelets is a signature of transcriptome degradation

Circular RNA expression in human hematopoietic cells is widespread and cell-type specific

Tumor-Educated Platelet RNA for the Detection and (Pseudo) progression Monitoring of Glioblastoma

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Diagnostic value of preoperative inflammatory markers in patients with glioma: A multicenter cohort study

Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival

Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival

Prognostic significance of preoperative neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in patients with glioma

Multi-biomarker panel signature as the key to diagnosis of ovarian cancer

Plasma Exosomal miRNA-139-3p is a Novel Biomarker of Colorectal Cancer

Uncharacterized RNAs in Plasma of Alzheimer's Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power

Haemolysis during sample preparation alters microRNA content of plasma

Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection

Droplet digital PCR for the detection and monitoring of Legionella pneumophila